Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection
Open Access
- 15 March 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 66 (6) , 1318-1323
Abstract
An experimental study was performed to evaluate both in vitro and in vivo the efficacy of clarithromycin coating combined with systemic amikacin in preventing ureteral stent biofilm infection due to Pseudomonas aeruginosa. The activities of the two antibiotics were studied in vitro in the absence or in the presence of biofilm. For the in vivo study we evaluated a control group without bacterial challenge to evaluate the sterility of the surgical procedure, a challenged control group that did not receive any antibiotic prophylaxis and three challenged groups that received (i) 15 mg/kg intraperitoneal amikacin immediately after stent implantation, (ii) clarithromycin-coated ureteral stents where 0.2 cm2 sterile ureteral stents were incubated in 10 mg/L clarithromycin solution for 30 min immediately before implantation, and (iii) intraperitoneal amikacin plus a clarithromycin-coated ureteral stent at the above concentrations. The in vitro studies showed that the biofilm was strongly affected by the presence of clarithromycin and, in its presence, amikacin had MICs and MBCs lower than those obtained in the absence of clarithromycin. For the singly treated groups, intraperitoneal amikacin showed the strongest effect on bacterial numbers. A clarithromycin coating combined with systemic amikacin showed an efficacy that was higher than that of each single compound. The prevention of ureteral stent Pseudomonas biofilm infection was enhanced by impregnation of the stent with clarithromycin combined with systemic amikacin.Keywords
This publication has 37 references indexed in Scilit:
- In vitro and in vivo model systems to study microbial biofilm formationJournal of Microbiological Methods, 2010
- Efficacy of the Combination of Tobramycin and a Macrolide in an I n V itro Pseudomonas aeruginosa Mature Biofilm ModelAntimicrobial Agents and Chemotherapy, 2010
- Recognition and prevention of healthcare-associated urinary tract infections in the intensive care unitCritical Care Medicine, 2010
- Urinary Tract Infection in Male General Practice Patients: Uropathogens and Antibiotic SusceptibilityUrology, 2010
- Novel Antiseptic Urinary Catheters for Prevention of Urinary Tract Infections: Correlation of In Vivo and In Vitro Test ResultsAntimicrobial Agents and Chemotherapy, 2009
- Effects of Combined Treatment with Sansanmycin and Macrolides on Pseudomonas aeruginosa and Formation of BiofilmBiomedical and Environmental Sciences, 2009
- Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing ofPseudomonas aeruginosaand Attenuates ChronicP. aeruginosaLung Infection inCftr−/−MiceAntimicrobial Agents and Chemotherapy, 2007
- URINARY TRACT BIOMATERIALSJournal of Urology, 2004
- Bacterial biofilms: from the Natural environment to infectious diseasesNature Reviews Microbiology, 2004
- Clarithromycin Pharmacokinetics in Healthy Young and Elderly VolunteersThe Journal of Clinical Pharmacology, 1992